<DOC>
	<DOCNO>NCT01219192</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability determine recommend dose treatment patient advance pancreatic cancer fist-line Gemcitabine treatment failure .</brief_summary>
	<brief_title>Study M2ES Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure</brief_title>
	<detailed_description>To evaluate safety tolerability determine recommend dose treatment patient advance pancreatic cancer fist-line Gemcitabine treatment failure.We star dose M2ES 15mg , escalate 30mg 45mg 60mg , find recommended dose clinic practise .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1. histologically cytologically confirm pancreatic adenocarcinoma amenable potentially curative surgery . 2 . All patient must develop progressive disease ( PD ) receive within 6 month discontinue palliative gemcitabinebased chemotherapy 3 . Prior radiation therapy allow provide site measurable disease locate within radiation port . 4 . 18 year age old 5 . Karnofsky performance status ( KPS ) 60100 point 6. measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 7 . Adequate hematologic , renal , hepatic function require deWned follow : WBC ≥3.5×109/L , absolute neutrophil count ≥ 1.5 × 109/L , platelet count ≥100 × 109/L , hemoglobin≥9g/dL , total bilirubin ≤2.5 upper limit normal [ ULN ] , AST≤2.5 ULN , or≤5 ULN evidence liver metastasis ; alkaline phosphatase≤ 2.5 ULN , or≤ 5 ULN evidence liver Metastases creatinine clearance≤50 mL/min , 8. life expectancy least 12 week 1. patient clinically apparent CNS metastases carcinomatous meningitis 2. another active malignancy , history malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix 3. 3 week interval last administration prior chemotherapy regimen study entry 4. 4 week interval last administration target therapy regimen study entry 5. major surgery within prior 6 week ; 6 . Pregnant lactate woman 7. tumor involvement major blood vessel 8. uncontrolled intercurrent illness 9 . A history myocardial infarction stroke within last 6 month , uncontrolled hypertension , unstable angina 10. clinically significant cardiac disease ( eg , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well control medication , myocardial infarction ) 11. urine protein ≥ 500 mg 24 hour ; 12. evidence bleed diathesis coagulopathy 13 . Patients therapeutic dos lowmolecular weight heparin 14 . Patients receive thrombolytic agent within previous month require fulldose anticoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>